Clearmind Medical (NASDAQ: CMND; FSE: CWY0) has announced positive permeation study results from its ongoing intranasal MEAI development program.
According to Clearmind, early-stage studies of its intranasal MEAI formulation have generated highly promising results, supporting the continued development of this innovative treatment approach as a differentiated therapeutic candidate for mental-health disorders, including alcohol use disorder (AUD), as well as for weight management, obesity, and metabolic conditions.
In a statement, Dr. Adi Zuloff Shani, CEO of Clearmind, commented, “These results represent an important milestone in our efforts to advance MEAI as a differentiated therapeutic candidate for AUD. The significantly enhanced nasal retention demonstrated by intranasal MEAI underscores the potential advantages of intranasal delivery as a promising administration route for MEAI. We are encouraged by the formulation’s ability to maintain prolonged contact with nasal tissue while demonstrating permeation characteristics comparable to a conventional MEAI formulation, and believe these findings further support the overall development program.”
